Axol Bioscience sign collaboration agreement with Metrion Biosciences

The agreement aims to improve, standardise and more accurately predict the risk of human clinical proarrhythmias. Metrion will use Axol's human iPSC-derived cardiomyocytes to carry out ion channel screening, cardiac safety testing and translational phenotypic assays. This is in accordance with the FDA's Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative, which aims to revise cardiac safety testing regulations.

Please click here for the full release.